SCHEMBL30608575

SCHEMBL30608575

CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NAA50 Q9GZZ1 1/20 0.49
▸ CXCL8 P10145 6/20 0.43
▸ CAPN1 P07384 2/20 0.43
▸ APLNR P35414 3/20 0.42
▸ NTSR1 P30989 1/20 0.41
▸ CRHR1 P34998 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ RAMP3 O60896 5/20 0.40
▸ CALCR P30988 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30608598 0.99 NAA50 (0.49) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608586 0.97 NAA50 (0.51) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608624 0.97 NAA50 (0.51) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608577 0.96 NAA50 (0.48) NAA50CAPN1NTSR1CRHR1CRHR2
SCHEMBL30608562 0.95 NAA50 (0.49) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608616 0.95 NAA50 (0.48) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608630 0.94 NAA50 (0.46) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608591 0.94 NAA50 (0.46) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608607 0.94 NAA50 (0.53) NAA50CXCL8CAPN1APLNRNTSR1
SCHEMBL30608626 0.94 NAA50 (0.53) NAA50CXCL8CAPN1APLNRNTSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646232-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY Université de Genève (CH) 2025-11-12 — — EP claimed
US-20250090637-A1 METHODS OF INHIBITING CEREBRAL INFLAMMATION UNIVERSITÉ DE GENÈVE (CH) 2025-03-20 — — US claimed
WO-2024146707-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY UNIVERSITÉ DE GENÈVE (CH) 2024-07-11 — — WO claimed
EP-3813870-B1 CCR5 INHIBITOR FOR USE IN TREATING CANCER ORION Biotechnology Switzerland Sarl (CH) 2023-11-15 — — EP claimed
EP-3813869-B1 CCR5 INHIBITOR FOR USE IN TREATING A NEUROINFLAMMATORY DISORDER THAT INVOLVES CEREBRAL INFLAMMATION UNIV GENEVE (CH) 2023-10-18 — — EP claimed
EP-4646232-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY Université de Genève (CH) 2025-11-12 — — EP disclosed
US-20250090637-A1 METHODS OF INHIBITING CEREBRAL INFLAMMATION UNIVERSITÉ DE GENÈVE (CH) 2025-03-20 — — US disclosed
CN-112469429-B Use of CCR5 inhibitors in cancer treatment 奥立安生物技术瑞士有限责任公司 2025-02-14 — — CN disclosed
CN-112469430-B Method for inhibiting cerebral inflammation 日内瓦大学 2024-12-24 — — CN disclosed
WO-2024146707-A1 VARIANT LIGAND CONJUGATES FOR PAYLOAD DELIVERY UNIVERSITÉ DE GENÈVE (CH) 2024-07-11 — — WO disclosed
EP-3813870-B1 CCR5 INHIBITOR FOR USE IN TREATING CANCER ORION Biotechnology Switzerland Sarl (CH) 2023-11-15 — — EP disclosed
EP-3813869-B1 CCR5 INHIBITOR FOR USE IN TREATING A NEUROINFLAMMATORY DISORDER THAT INVOLVES CEREBRAL INFLAMMATION UNIV GENEVE (CH) 2023-10-18 — — EP disclosed
Send feedback